I think it could safely be said that if funded, GNVC could contribute to the effort directed against Zika. The point is, they've not announced such funding, and it's very unlikely they're doing anything against this threat without funds.
I've really not followed CVM closely, but if they've not issued a PR on how their drug, Multikine, will shortly be starting a Phase III Trial against Zika. I say this not because I think it has a chance, but rather because it's been proven safe enough for several Phase III Trials, which all have failed, but the FDA welcomes them to try others. I view their drugs as a cure in search of a disease, perhaps some day they'll find it.
What the PR doesn't say is that it's release anticipates a big jump in share price, and on that jump they intend to issue a lot of new shares. It's this tact that's kept them in business for decades. When a drug maker makes a statement that's as positive as most of that CVM makes, their are always some investors who don't look at their history. A look at GNVC's history might look similar to some, but it isn't. The difference is that GNVC's developed several drugs that are unrelated, and they've partially sponsored by the like of Novartis, NIH, Gate's Initiative, etc. while CVM just keeps rolling out old previously failed drugs, and saying they feel certain they're the cure for whatever the disease of the year is.
Gary
AI
